Trials / Completed
CompletedNCT06912932
Physiological and Perceptual Responses During 4-Second Exercise
The Effects of The Exercise Intensity and Rest Duration on Physiological and Perceptual Responses During 4-Second Sprint Interval Exercise
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- University of Texas at Austin · Academic / Other
- Sex
- All
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the acute effects of different intensities (i.e., 50, 75, and 100% of maximal anaerobic power) of 4-s sprint interval exercise on physiological responses. Secondly, it will determine the relationship between intensity and recovery duration (i.e., 15, 30, or 45-s) that will stimulate the cardiovascular and metabolic systems.
Detailed description
Background Short sprint interval training (sSIT) is typically performed at maximal intensity, generating power far above what is needed to reach peak oxygen consumption (VO₂peak). However, the physiological effects of submaximal sprint intensities and different recovery periods are not well understood. Study Aim This study examined how power output and oxygen consumption (VO₂) respond to repeated 4-second sprints at 50%, 75%, and 100% of maximal power (Pmax) with rest periods of 15, 30, or 45 seconds. Methods Eleven recreationally active participants completed nine trials, each consisting of thirty 4-second cycling sprints under different intensity and recovery conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Preventive | systematically investigate the acute physiological responses induced by three levels of %Pmax intensities (50% and 75% of Pmax and all-out efforts) with three varying rest periods (15, 30, and 45-s) between thirty 4-s sprints. |
Timeline
- Start date
- 2023-04-04
- Primary completion
- 2024-10-02
- Completion
- 2024-10-02
- First posted
- 2025-04-06
- Last updated
- 2025-04-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06912932. Inclusion in this directory is not an endorsement.